Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward?
Identifieur interne : 000A31 ( Main/Exploration ); précédent : 000A30; suivant : 000A32Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward?
Auteurs : Olle Lindvall [Suède]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- methods : Cell- and Tissue-Based Therapy.
- physiology : Dopaminergic Neurons.
- surgery : Parkinson Disease.
- Animals, Humans.
Abstract
Despite 3 decades of basic and clinical studies, there is still no dopaminergic cell therapy for Parkinson's disease. Several arguments have been put forward why this approach, so far tested with transplantation of human fetal mesencephalic dopamine-rich tissue, will never be of clinical use and should be abandoned: (1) Lack of efficacy in 2 sham surgery-controlled trials; (2) occurrence of troublesome off-medication dyskinesias in a subgroup of grafted patients; (3) disease process destroys grafted neurons; and (4) non-motor symptoms will not be influenced by intrastriatal dopaminergic grafts. Here, the author argues that, based on recent scientific advancements, the development of a dopaminergic cell therapy for Parkinson's disease should continue. Factors influencing the outcome after transplantation have now been identified, and dopaminergic neurons can be generated in large numbers from stem cells. Mechanisms of graft-induced dyskinesias are much better understood, and patients with well functioning grafts can exhibit long-term motor recovery of therapeutic value even in the presence of non-motor symptoms.
DOI: 10.1002/mds.25378
PubMed: 23401015
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A61
- to stream PubMed, to step Curation: 000A61
- to stream PubMed, to step Checkpoint: 000A40
- to stream Ncbi, to step Merge: 003A20
- to stream Ncbi, to step Curation: 003A20
- to stream Ncbi, to step Checkpoint: 003A20
- to stream Main, to step Merge: 000A31
- to stream Main, to step Curation: 000A31
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward?</title><author><name sortKey="Lindvall, Olle" sort="Lindvall, Olle" uniqKey="Lindvall O" first="Olle" last="Lindvall">Olle Lindvall</name><affiliation wicri:level="1"><nlm:affiliation>Lund Stem Cell Center, University Hospital, Lund, Sweden. olle.lindvall@med.lu.se</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Lund Stem Cell Center, University Hospital, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="doi">10.1002/mds.25378</idno><idno type="RBID">pubmed:23401015</idno><idno type="pmid">23401015</idno><idno type="wicri:Area/PubMed/Corpus">000A61</idno><idno type="wicri:Area/PubMed/Curation">000A61</idno><idno type="wicri:Area/PubMed/Checkpoint">000A40</idno><idno type="wicri:Area/Ncbi/Merge">003A20</idno><idno type="wicri:Area/Ncbi/Curation">003A20</idno><idno type="wicri:Area/Ncbi/Checkpoint">003A20</idno><idno type="wicri:Area/Main/Merge">000A31</idno><idno type="wicri:Area/Main/Curation">000A31</idno><idno type="wicri:Area/Main/Exploration">000A31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward?</title><author><name sortKey="Lindvall, Olle" sort="Lindvall, Olle" uniqKey="Lindvall O" first="Olle" last="Lindvall">Olle Lindvall</name><affiliation wicri:level="1"><nlm:affiliation>Lund Stem Cell Center, University Hospital, Lund, Sweden. olle.lindvall@med.lu.se</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Lund Stem Cell Center, University Hospital, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cell- and Tissue-Based Therapy (methods)</term><term>Dopaminergic Neurons (physiology)</term><term>Humans</term><term>Parkinson Disease (surgery)</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cell- and Tissue-Based Therapy</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Dopaminergic Neurons</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite 3 decades of basic and clinical studies, there is still no dopaminergic cell therapy for Parkinson's disease. Several arguments have been put forward why this approach, so far tested with transplantation of human fetal mesencephalic dopamine-rich tissue, will never be of clinical use and should be abandoned: (1) Lack of efficacy in 2 sham surgery-controlled trials; (2) occurrence of troublesome off-medication dyskinesias in a subgroup of grafted patients; (3) disease process destroys grafted neurons; and (4) non-motor symptoms will not be influenced by intrastriatal dopaminergic grafts. Here, the author argues that, based on recent scientific advancements, the development of a dopaminergic cell therapy for Parkinson's disease should continue. Factors influencing the outcome after transplantation have now been identified, and dopaminergic neurons can be generated in large numbers from stem cells. Mechanisms of graft-induced dyskinesias are much better understood, and patients with well functioning grafts can exhibit long-term motor recovery of therapeutic value even in the presence of non-motor symptoms.</div></front></TEI><affiliations><list><country><li>Suède</li></country></list><tree><country name="Suède"><noRegion><name sortKey="Lindvall, Olle" sort="Lindvall, Olle" uniqKey="Lindvall O" first="Olle" last="Lindvall">Olle Lindvall</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23401015
|texte= Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23401015" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |